These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9421359)

  • 1. int-2 oncogene amplification and prognosis in node-negative breast carcinoma.
    Fioravanti L; Cappelletti V; Coradini D; Miodini P; Borsani G; Daidone MG; Di Fronzo G
    Int J Cancer; 1997 Dec; 74(6):620-4. PubMed ID: 9421359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH; Bièche I; Hacène K; Lidereau R
    Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis.
    Ottestad L; Andersen TI; Nesland JM; Skrede M; Tveit KM; Nustad K; Børresen AL
    Acta Oncol; 1993; 32(3):289-94. PubMed ID: 8100712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
    Berns EM; Foekens JA; van Staveren IL; van Putten WL; de Koning HY; Portengen H; Klijn JG
    Gene; 1995 Jun; 159(1):11-8. PubMed ID: 7607564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.
    Hui R; Campbell DH; Lee CS; McCaul K; Horsfall DJ; Musgrove EA; Daly RJ; Seshadri R; Sutherland RL
    Oncogene; 1997 Sep; 15(13):1617-23. PubMed ID: 9380415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors.
    Berns EM; Klijn JG; van Staveren IL; Portengen H; Noordegraaf E; Foekens JA
    Eur J Cancer; 1992; 28(2-3):697-700. PubMed ID: 1350457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of amplified int-2/FGF-3 gene in primary breast carcinomas using differential polymerase chain reaction.
    Naidu R; Wahab NA; Yadav M; Kutty MK; Nair S
    Int J Mol Med; 2001 Aug; 8(2):193-8. PubMed ID: 11445874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse.
    Roux-Dosseto M; Romain S; Dussault N; Desideri C; Piana L; Bonnier P; Tubiana N; Martin PM
    Eur J Cancer; 1992; 28A(10):1600-4. PubMed ID: 1356387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Abnormalities and clinical characteristics of growth factors and receptor systems in breast cancer].
    Kikuchi K; Ueda M; Ikeda T; Enomoto K; Kitajima M
    Gan To Kagaku Ryoho; 1994 Jun; 21 Suppl 2():168-71. PubMed ID: 7913599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. int-2 amplification in breast cancer: association with decreased survival and relationship to amplification of c-erbB-2 and c-myc.
    Henry JA; Hennessy C; Levett DL; Lennard TW; Westley BR; May FE
    Int J Cancer; 1993 Mar; 53(5):774-80. PubMed ID: 8449602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERBB2 amplification in breast cancer with a high rate of proliferation.
    Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Sigurdsson H
    Oncogene; 1991 Jan; 6(1):137-43. PubMed ID: 1671531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogene amplification per se: an independent prognostic factor in human breast cancer.
    Champème MH; Bièche I; Hacène K; Lidereau R
    Mol Carcinog; 1994 Dec; 11(4):189-91. PubMed ID: 7999260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer.
    Meyer JS; Province MA
    Cancer; 1994 Oct; 74(8):2287-99. PubMed ID: 7922981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes.
    Pauley RJ; Gimotty PA; Paine TJ; Dawson PJ; Wolman SR
    Breast Cancer Res Treat; 1996; 37(1):65-76. PubMed ID: 8750529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis.
    Børresen AL; Ottestad L; Gaustad A; Andersen TI; Heikkilä R; Jahnsen T; Tveit KM; Nesland JM
    Br J Cancer; 1990 Oct; 62(4):585-90. PubMed ID: 1977466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A paradigm for oncogene complementation in human breast cancer.
    Roux-Dosseto M; Martin PM
    Res Virol; 1989; 140(6):571-91. PubMed ID: 2694252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness.
    Brouillet JP; Theillet C; Maudelonde T; Defrenne A; Simony-Lafontaine J; Sertour J; Pujol H; Jeanteur P; Rochefort H
    Eur J Cancer; 1990 Apr; 26(4):437-41. PubMed ID: 2141510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-myc amplification is an independent prognostic factor in postmenopausal breast cancer.
    Borg A; Baldetorp B; Fernö M; Olsson H; Sigurdsson H
    Int J Cancer; 1992 Jul; 51(5):687-91. PubMed ID: 1612775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.